Claims for Patent: 10,869,844

Summary for Patent: 10,869,844

Title:	Methods for the treatment of depression
Abstract:	The present invention is directed to methods and dosing regimens for the treatment of depression (preferably, treatment resistant depression), for the treatment of depression in a suicidal patient, and/or for the treatment and/or prevention of suicidality (e.g. suicidal ideations).
Inventor(s):	Caers; Lodewijk Ivo (Beerse, BE), Singh; Jaskaran (San Diego, CA), Zannikos; Peter Nicholas (Doylestown, PA), Drevets; Wayne C. (Rancho Santa Fe, CA), Daly; Ella (Doylestown, PA), Canuso; Carla Marie (Yardley, PA), Fedgchin; Margaret (Collegeville, PA), Wiegand; Frank (Annandale, NJ)
Assignee:	Janssen Pharmaceutica NV (Beerse, BE)
Application Number:	16/727,594
Patent Claims:	1. A method of treating major depressive disorder in a human patient in need thereof, comprising: intranasally administering (S)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone in an induction dosage to the patient in an amount in the range of from about 56 mg to about 84 mg in an induction phase, wherein the induction phase comprises a treatment period of about four weeks, and the induction dosage is administered at a frequency of twice per week during the induction phase. 2. The method of claim 1, wherein the induction dosage is about 56 mg or about 84 mg. 3. The method of claim 2, wherein the patient exhibits suicidal ideation or behavior. 4. The method of claim 2, wherein the major depressive disorder is treatment resistant depression. 5. The method of claim 2, further comprising adjunctive treatment with a therapeutically effective amount of one or more antidepressants during the induction phase. 6. The method of claim 5, wherein the patient exhibits suicidal ideation or behavior. 7. The method of claim 6, wherein the (S)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone is administered as its corresponding hydrochloride salt during the induction phase. 8. The method of claim 7, wherein the one or more antidepressants is an oral antidepressant. 9. The method of claim 5, wherein the major depressive disorder is treatment resistant depression. 10. The method of claim 9, wherein the (S)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone is administered as its corresponding hydrochloride salt during the induction phase. 11. The method of claim 2, wherein the induction dosage is about 84 mg. 12. The method of claim 11, wherein the depression major depressive disorder is treatment resistant depression. 13. The method of claim 11, wherein the patient exhibits suicidal ideation or behavior. 14. The method of claim 11, further comprising adjunctive treatment with a therapeutically effective amount of one or more antidepressants during the induction phase. 15. The method of claim 14, wherein the patient exhibits suicidal ideation or behavior. 16. The method of claim 15, wherein the (S)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone is administered as its corresponding hydrochloride salt during the induction phase. 17. The method of claim 14, wherein the major depressive disorder is treatment resistant depression. 18. The method of claim 17, wherein the (S)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone is administered as its corresponding hydrochloride salt during the induction phase. 19. The method of claim 1, wherein the (S)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone is administered as its corresponding hydrochloride salt during the induction phase. 20. A method of treating depression in a human patient in need thereof, the method having an induction phase and a subsequent maintenance phase, comprising: intranasally administering (S)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone in an induction dosage to the patient in an amount in the range of from about 28 mg to about 84 mg in the induction phase, wherein the induction phase comprises a treatment period of about four weeks, and the induction dosage is administered at a frequency of twice per week during the induction phase; and intranasally administering (S)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone in a maintenance dosage in an amount in the range of from about 56 mg to about 84 mg in the maintenance phase, wherein the maintenance dosage is administered at a frequency of once per week or once every two weeks. 21. The method of claim 20, wherein the induction dosage is about 56 mg or about 84 mg, and the maintenance dosage is about 56 mg or about 84 mg. 22. The method of claim 21, wherein the depression is major depressive disorder. 23. The method of claim 21, wherein the depression is treatment resistant depression. 24. The method of claim 21, further comprising adjunctive treatment with a therapeutically effective amount of one or more antidepressants during the induction phase and the maintenance phase. 25. The method of claim 24, wherein the depression is major depressive disorder. 26. The method of claim 25, wherein the (S)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone is administered as its corresponding hydrochloride salt during the induction phase and maintenance phase. 27. The method of claim 24, wherein the depression is treatment resistant depression. 28. The method of claim 27, wherein the (S)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone is administered as its corresponding hydrochloride salt during the induction phase and maintenance phase. 29. The method of claim 28, wherein the one or more antidepressants is an oral antidepressant. 30. The method of claim 20, wherein the (S)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone is administered as its corresponding hydrochloride salt during the induction phase and maintenance phase.